Timothy Cloughesy
University of California, Los Angeles
H-index: 132
North America-United States
Top articles of Timothy Cloughesy
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma | Isabel Arrillaga-Romany Andrew Lassman Susan L McGovern Sabine Mueller Burt Nabors | 2024/3/6 | |
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial | Nature medicine | Ingo K Mellinghoff Min Lu Patrick Y Wen Jennie W Taylor Elizabeth A Maher | 2024 |
Compositions and methods for treating cancer | 2014/6/12 | ||
dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma | Journal of Neuro-oncology | Serendipity Zapanta Rinonos Tie Li Sean Thomas Pianka Terry J Prins Blaine SC Eldred | 2024/1 |
Selective DRD2 Antagonist and ClpP Agonist ONC201 in a Recurrent Non-midline H3 K27M-mutant Glioma Cohort | Yazmin Odia Matthew D Hall Timothy Francis Cloughesy Patrick Y Wen Isabel Arrillaga-Romany | 2024/2/22 | |
pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells | Neuro-oncology | Kunal S Patel Jingwen Yao Nicholas S Cho Francesco Sanvito Kaleab Tessema | 2024/1/1 |
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma | Journal of Clinical Oncology | Isabel Arrillaga-Romany Sharon L Gardner Yazmin Odia Dolly Aguilera Joshua E Allen | 2024/2/9 |
A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life … | Katherine Peters Ingo Mellinghoff Martin Van Den Bent Deborah Blumenthal Mehdi Touat | 2024/4/14 | |
Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction | American Journal of Neuroradiology | Nicholas S Cho Francesco Sanvito Viên Lam Le Sonoko Oshima Ashley Teraishi | 2024/2/1 |
D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation | Cancer Research Communications | Sean T Pianka Tie Li Terry J Prins Blaine SC Eldred Bryan M Kevan | 2024/3/22 |
498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma | Annals of Oncology | D Blumenthal IK Mellinghoff MJ van den Bent M Touat K Peters | 2023/10/1 |
P11. 29. B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA | Neuro-oncology (Charlottesville, Va.) | M Weller B Alexander D Berry N Blondin M Buxton | 2023/9/8 |
CTNI-51. A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2 DIFFUSE GLIOMA (INDIGO … | Neuro-Oncology | Timothy Cloughesy Ingo Mellinghoff Martin van den Bent Deborah Blumenthal Mehdi Touat | 2023/11/1 |
NIMG-62. QUANTITATIVE ASSESSMENT OF T2-FLAIR MISMATCH IN HUMAN NON-ENHANCING GLIOMAS USING SUBTRACTION MAPS OF T2-W AND FLAIR MRI | Neuro-Oncology | Nicholas Cho Francesco Sanvito Vien Le Sonoko Oshima Ashley Teraishi | 2023/11/1 |
Federated learning enables big data for rare cancer boundary detection (vol 13, 7346, 2022) | Nature communications | Sarthak Pati Ujjwal Baid Brandon Edwards Micah Sheller Shih-Han Wang | 2022/12/5 |
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized … | Neuro-oncology | Antonio Omuro Alba A Brandes Antoine F Carpentier Ahmed Idbaih David A Reardon | 2023/1/1 |
Non-invasive functional companion assays for oncogene targeted therapy for brain cancer | 2023/11/9 | ||
Retrospective examination of pseudoprogression in IDH mutant gliomas | Neuro-oncology advances | Ethan A Wetzel Matthew J Farrell Blaine SC Eldred Vicki Liu Ishan Saha | 2023/1/1 |
Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma | Cancer Research | Isabel Arrillaga-Romany Andrew Lassman Susan L McGovern Sabine Mueller Louis B Nabors | 2023/4/14 |
Ombipepimut dosing emulsion (ODE)+ bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM). | Samuel Aaron Goldlust Jong Hee Chang Yoshitaka Narita Mary Roberta Welch Richard M Green | 2023/6/1 |
Co-Authors
